The Clinical Core performs comprehensive clinical and neuropsychological patient evaluations, coordinates data transfer to the Data Management Core, and conducts longitudinal follow up of elders with normal cognition, mild cognitive impairment and with Alzheimer's disease and other dementias. The Clinical Core coordinates recruitment of subjects for the Mount Sinai ADRC, the Alzheimer's Disease Cooperative Study (ADCS), the National Alzheimer's Coordinating Center (NACC) and other National Institute of Health funded studies, and non-funded pilot studies. In its ongoing efforts to serve a diverse population, the Clinical Core maintains a Satellite Diagnostic and Treatment Clinic for the recruiment of minorty poulations. This Core works on the development of method for research in Alzheimer's and provides training to a wide range of researchers to assist in the collection of data in related areas. The Core approaches all participants for the autopsy program. Antemortem clinical information on all autopsied cases is provided to the Neuropathology Core through the data management core. Educational and outreach activities are conducted in conjunction with the Education Information Transfer Core.

Public Health Relevance

Alzheimer's disease is expected to claim 8 million victims within the next 25 years. There is no means of preventing or reversing the disease. The actiivtes proposed in this application will provide research particpants for entire spectrum of studies needed to understand the mechanisms of the disease and with which to develop effective treatments. These studies, ranging from molecular studies of tissue specmens to imaging to clinical trials all require the richly charcaterized subjects provided by the Core.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005138-28
Application #
8440865
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2012-04-15
Budget End
2013-03-31
Support Year
28
Fiscal Year
2012
Total Cost
$273,739
Indirect Cost
$88,337
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Gandal, Michael J; Haney, Jillian R; Parikshak, Neelroop N et al. (2018) Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Science 359:693-697
Huckins, L M; Hatzikotoulas, K; Southam, L et al. (2018) Investigation of common, low-frequency and rare genome-wide variation in anorexia nervosa. Mol Psychiatry 23:1169-1180
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Ki?emet-Piska?, Spomenka; Babi? Leko, Mirjana; Blažekovi?, Antonela et al. (2018) Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. CNS Neurosci Ther 24:734-740
Soleimani, Laili; Ravona-Springer, Ramit; Heymann, Anthony et al. (2018) Depression is more strongly associated with cognition in elderly women than men with type 2 diabetes. Int Psychogeriatr :1-5
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Audrain, Mickael; Haure-Mirande, Jean-Vianney; Wang, Minghui et al. (2018) Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Mol Psychiatry :
Boban, Mirta; Babi? Leko, Mirjana; Miški?, Terezija et al. (2018) Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species. J Neurosci Methods :
Zhu, Carolyn W; Grossman, Hillel; Neugroschl, Judith et al. (2018) A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y) 4:609-616

Showing the most recent 10 out of 555 publications